The use of bioinformatics in developing targeted therapies for high-risk leukemiasData mining, bioinformatics, computational modeling and simulation have increasingly become integral to development of novel hypotheses in disease progression and potentially novel therapeutic innovations. Recent development of dynamic algorithms that allow rapid analysis of publicly available datasets directly relevant to childhood leukemia provide a unique opportunity for a biomedical revolution that can provide the foundation for therapeutic innovations aimed at eradicating childhood leukemia utilizing more specifically defined targets exhibiting more favorable toxicity profiles. My research seeks to take advantage of these opportunities to train independent and creative scientists who in a collaborative environment are capable in tackling complex diseases such as cancer. We have gained unprecedented molecular detail in the emergence and progression of cancer cells through the development of many high-throughput technologies and the query of these datasets in curated databases to envision a new paradigm of therapeutic innovations. As we increase our understanding of the molecular events that result in the emergence of cancer cells, we hope to be able to target these cells at the earliest of stages employing novel nano-technology platforms. I have active collaborations with the Children’s Hospital Los Angeles and the National Cancer Institute Alliance for Nanotechnology in Cancer with aims to integrate Bioinformatics, Computational Biology with development of novel nano-particles to target childhood leukemias.
Peer reviewed Publications with Students.
Jason J. Pitt and Sanjive Qazi. “Phenotypes for Prediction: Gene Expression and Genetic Exceptionalism.” eJournal of Biological sciences Volume 2, Issue 1 (January-March, 2010) pp 52
Sanjive Qazi, N. L. Soiseth and F. M. Uckun. “Early Detection of Subtype-Specific HIV-1 Infection Using Transcriptomes from Host Cell Responses.” eJournal of Biological sciences Volume 2, Issue 1 (January-March, 2010) pp 65.
Uckun FM, Pitt J, Qazi S. JAK3 pathway is constitutively active in B-lineage acute lymphoblastic leukemia. (2011). Expert Rev Anticancer Ther. Jan;11(1):37-48. Epub 2010 Nov 11. Review
Uckun FM, Qazi S, Ozer Z, Garner AL, Pitt J, Ma H, Janda KD (2011). Inducing apoptosis in chemotherapy-resistant B-lineage acute lymphoblastic leukaemia cells by targeting HSPA5, a master regulator of the anti-apoptotic unfolded protein response signalling network. Br J Haematol. Jun;153(6):741-52.
B.S. University of Sheffield, Sheffield, U.K.; PhD, CASE Bath University, U.K.
Areas of Expertise
- SYK mediated chemo-resistance mechanism in ALL
- Gene expression in HIV diagnosis
- Gene expression Genetic Exceptionalism
- Anti-HIV compound Stampidine 1 in Mice
- Anti-HIV Compound Stampidine 2 Cell lines
- Anti-HIV compound Stampidine 3 Cats
- GABA receptor: Neural Correlate of Consciousness?
- Insect Biochemistry NO/cGMP
- Inhibition of sperm_Structure Activity
- HIV Gene expression profiling IMA presentation
- CD22 B-cell Leukemias
- JAK3 Inhibitor in Nano-particle form
- Math in Medicine Workshop_Bone cells
- ALL Infant Gene Expression
- Vinorelbine therapy ALL
- Epigenetics of Stampidine Stampidine silences HDFs
- SYK phosphorylation of Ikaros
- E2A_PBX_antisense CD19 antibody linked to E2A-PBX antisense molecule
- SYK_STAT3 Gene expression meta-analysis of SYK-STAT3 activation in BPL
- IKZF1deletions.pdf Lack of IKZF1 deletions in BPL
- Nanoscale_C61 Nano-formulation of C61 to inhibit SYK
BIO-102 (Organismal Biology Lab), BIO-218 (Microbio Lab), and BIO-397 (Honors Thesis)
|Synonym||Title||Times Taught||Terms Taught|
|BIO-201||Cell Biology Lab||32||2015/FA, 2014/FA, 2013/FA, 2012/FA, 2011/FA, 2010/FA, 2009/FA, 2008/FA, and 2007/FA|
|BIO-118||Microbes and Human Health Lab||21||2014/SP, 2013/SP, 2012/SP, 2011/SP, 2010/SP, 2009/SP, and 2008/SP|
|BIO-201||Cell and Molecular Biology||18||2015/FA, 2014/FA, 2013/FA, 2012/FA, 2011/FA, 2010/FA, 2009/FA, 2008/FA, and 2007/FA|
|BIO-102||Organismal Biology Lab||10||2014/SP, 2012/SP, 2011/SP, 2010/SP, 2009/SP, and 2008/SP|
|BIO-268||Career Exploration||10||2014/JN, 2013/JN, 2012/JN, 2010/JN, 2009/JN, and 2008/JN|
|NDL-268||Career Exploration||4||2016/JN, 2014/JN, 2013/JN, and 2012/JN|
|BIO-108||Neurobiology: Emotions||3||2016/JN, 2011/JN, and 2008/JN|
|BIO-392||Biology Research||3||2010/FA, 2009/FA, and 2009/SP|